Italy's Diasorin confirms 2026 guidance, sees 6-8% yearly sales growth until 2030
20/05/2026 10:34
May 20 (Reuters) - Italy's Diasorin DIAS.MI confirmed its 2026 guidance on Wednesday and announced a new 2026-2030 business plan ahead of a presentation to investors. The medical diagnostics firm said it expected average revenue growth of 6% to 8% per year at constant exchange rates between 2026 and 2030. That is slightly above the 5% to 6% growth guidance for 2026. (Reporting by Anna Uras, editing by Milla Nissi-Prussak) ((Anna.Uras@thomsonreuters.com;))
Recent news on DiaSorin SpA
See all newsKepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest